share_log

復宏漢霖:自願公告 - 注射用HLX42(靶向EGFR抗體- 新型DNA拓撲異構酶I抑制劑偶聯藥物)在晚期/轉移性實體瘤患者中開展的1期臨床研究於中國境內完成首例患者給藥

HENLIUS: VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX42 FOR INJECTION (ANTIBODY-DRUG CONJUGATE TARGETING EGFR WITH NOVEL DNA TOPOISOMERASE I INHIBITOR) FOR THE TREATMENT OF ADVANCE/METASTATIC SOLID TUMOURS IN

香港交易所 ·  Mar 14 09:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more